A Novel Metabolic Liver Fibrosis Risk Score for the Identification of Elevated Liver Stiffness in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Study

In this pilot cohort of patients with MASLD, the newly derived Metabolic Liver Fibrosis Risk Score (MLFRS), combining age, body mass index, HbA1c and AST, discriminated VCTE-defined elevated liver stiffness better than BARD and FIB-4, and non-significantly better than the NAFLD Fibrosis Score, while requiring fewer laboratory measurements. The endpoint was elevated liver stiffness, not histological fibrosis; external validation is required.